8-K: Rezolute Announces Positive Update on Phase 3 sunRIZE Study for Congenital Hyperinsulinism Treatment

Rezolute reports positive outcomes from the Data Monitoring Committee review of the open-label arm of its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism, allowing enrollment of infants into the double-blind portion of the study.

Summary

• Rezolute, Inc. announced an update on its Phase 3 sunRIZE study of ersodetug for treating hypoglycemia due to congenital hyperinsulinism.
• The Data Monitoring Committee (DMC) reviewed the open-label arm (OLA) of the study, which included infant participants under 1 year old.
• The DMC found that target drug concentrations were safely reached at the tested doses of 5 or 10 mg/kg administered bi-weekly and monthly.
• The DMC approved the enrollment of infants into the double-blind portion of the study.
• Study enrollment completion is expected in Q2 2025, with topline results anticipated in Q4 2025, pending the outcome of an interim analysis (IA).
• The interim analysis will assess the adequacy of the sample size for the primary endpoint and may recommend increasing the sample size by 33% (18 additional patients).
• If the sample size is increased, enrollment completion would shift to Q4 2025, and topline results would be available in mid-2026.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the favorable safety data, DMC approval to proceed with the double-blind study, and the Breakthrough Therapy Designation from the FDA. However, the potential for a study delay due to sample size adjustments tempers the overall optimism.

Positives

• Ersodetug demonstrated a favorable safety profile in young infants.
• Drug levels achieved were consistent with those seen in previous studies where efficacy was observed.
• The DMC's approval to proceed with the double-blind portion of the study is a positive milestone.
• The FDA granted Breakthrough Therapy Designation for ersodetug.

Risks

• The interim analysis could recommend increasing the sample size, potentially delaying the availability of topline results to mid-2026.
• The interim analysis could determine futility and the study should be stopped.
• The study is subject to the recommendations from the DMC based on the upcoming interim analysis.

Future Outlook

Rezolute anticipates study enrollment completion in Q2 2025 and topline results in Q4 2025, contingent on the outcome of the interim analysis. The interim analysis may recommend increasing the sample size, which could shift the timeline for topline results to mid-2026.

Management Comments

• Brian Roberts, M.D., Chief Medical Officer at Rezolute, stated that the preliminary outcomes from the open label arm of the sunRIZE study are encouraging, particularly as it is a strong indication of the safety profile of ersodetug and provides additional validation of the selected doses in very young participants.
• Brian Roberts, M.D., Chief Medical Officer at Rezolute, stated that having recently received Breakthrough Therapy Designation from the FDA, 2025 has already been an exciting year for Rezolute and we look forward to additional milestones over the course of this year as we progress in our mission to provide a safe and effective therapy for people living with hyperinsulinism.

Industry Context

This announcement is relevant to the rare disease and biopharmaceutical industries, specifically concerning the development of treatments for congenital hyperinsulinism. The positive safety data and progress in the Phase 3 trial could position Rezolute as a key player in this therapeutic area.

Comparison to Industry Standards

• Other companies developing therapies for congenital hyperinsulinism include Zealand Pharma and Crinetics Pharmaceuticals.
• Zealand Pharma's dasiglucagon is a glucagon analog used to treat hypoglycemia, while Crinetics Pharmaceuticals is developing paltusotine, a somatostatin receptor type 2 (SST2) agonist.
• Rezolute's ersodetug, a monoclonal antibody, represents a different approach by targeting the insulin receptor directly.
• The Phase 3 sunRIZE study is designed to evaluate the efficacy and safety of ersodetug in patients with congenital HI who are experiencing poorly controlled hypoglycemia, similar to the goals of other companies' clinical trials in this space.

Stakeholder Impact

• Positive news for patients with congenital hyperinsulinism and their families, as it indicates progress towards a potential new treatment option.
• Potential benefit for Rezolute shareholders due to the advancement of the company's lead drug candidate.
• Positive impact on the medical community through the development of a novel therapy for a rare disease.

Next Steps

• Continue enrollment in the double-blind portion of the sunRIZE study.
• Conduct the interim analysis of the study primary hypoglycemia endpoint at the end of Q1 2025.
• Announce the conclusions of the DMC early in Q2 2025.
• Await topline results in Q4 2025 or mid-2026, depending on the outcome of the interim analysis.

Key Dates